NCT01358565View on ClinicalTrials.gov

Pharmacokinetics Of Orally Administered Fx-1006A In Subjects With Hepatic Dysfunction

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions
Mild Hepatic DysfunctionModerate Hepatic Dysfunction
Interventions
DRUG

Fx-1006A

A single oral 20 mg dose of Fx-1006A will be administered on Day 1 followed by 16 days of follow-up.

DRUG

Fx-1006A

A single oral 20 mg dose of Fx-1006A will be administered on Day 1 followed by 16 days of follow-up.

Trial Locations (1)

6045

Pfizer Investigational Site, Newton Park

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY